Trial Profile
Comparing the Dynamics of Different HIV-1 cDNA Species in CD4-positive T-cells and HIV-1 RNA in Plasma of Infected Individuals After Initiation of Antiretroviral Therapy With or Without Raltegravir
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Efavirenz; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors; Peptide hydrolase inhibitors
- Indications HIV-1 infections
- Focus Pharmacodynamics
- 10 Nov 2015 Status changed from recruiting to completed as per results published in the Journal of Antimicrobial Chemotherapy
- 04 Dec 2012 New trial record